Pyxis Oncology’s (PYXS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $5.00 target price on the stock.

PYXS has been the topic of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Up 0.9 %

Shares of PYXS opened at $1.07 on Wednesday. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18. The firm’s 50 day moving average price is $1.34 and its 200 day moving average price is $2.39. The company has a market cap of $63.63 million, a P/E ratio of -1.04 and a beta of 1.11.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Tuesday, March 18th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. Research analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of PYXS. ProShare Advisors LLC purchased a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $26,000. Caption Management LLC acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Ameriprise Financial Inc. acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at $35,000. Commonwealth Equity Services LLC boosted its holdings in shares of Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock valued at $41,000 after buying an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new position in shares of Pyxis Oncology in the 4th quarter valued at $47,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.